Trials / Not Yet Recruiting
Not Yet RecruitingNCT06770881
JSKN033 in Chinese Subjects with Advanced Malignant Tumors
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN033 in Chinese Subjects with Advanced Malignant Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 430 (estimated)
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I/II multicenter study to evaluate the safety and efficacy of JSKN033 in Chinese subjects with unresectable locally advanced/metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JSKN033 | JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle |
Timeline
- Start date
- 2025-01-15
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2025-01-13
- Last updated
- 2025-01-13
Source: ClinicalTrials.gov record NCT06770881. Inclusion in this directory is not an endorsement.